AccelStor Announces New Flagship All-Flash Array: The NeoSapphire P710
AccelStor, the software-defined all-flash array provider, is thrilled to announce the next generation NeoSapphire P710, its latest flagship all-flash array. The P710 pushes performance to a new level: over 700K IOPS for 4KB random writes. It adds abundant software features including snapshot, snapshot backup, Free Clone, thin provisioning, thick provisioning, inline deduplication (Zero Page) and vSphere Web Client Plug-in, with zero performance trade-offs. All these make the P710 perfect for VDI environments and the first choice for users that need high performance combined with versatile software functions and data protection features. With a wealth of software advantages, the NeoSapphire P710 is apt for any demanding applications.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161207005019/en/
AccelStor New Flagship All-Flash Array: NeoSapphire P710 (Photo: Business Wire)
“The big data and VDI revolution are driving new requirements for our customers, and pushes the limits of our design team,” said Dr. Charles Tsai, President of AccelStor, “By broadening our software functionality, including new tools for VDI environments, we’re determined to be the go-to solution for any I/O intensive storage applications.”
A New Level of Storage Performance
Supported by FlexiRemap Technology, the NeoSapphire P710 all-flash array boasts the highest IOPS of the series – over 700K IOPS for 4KB random write, an over 16% increase from its predecessor, the NeoSapphire 3413. The P710 comes with 11TB or 23TB usable capacity and adopts the same rack-mount 2U form factor, storing up to 24 hot-swappable enterprise SSDs including 2 global hot spares. This new generation of all-flash arrays supports both 10GbE and 16G Fibre Channel connectivity for blazing-fast throughput.
Snapshots for Software-Level Protection
With the P710, NeoSapphire users can now quickly and seamlessly recover their data to particular instances through its snapshot function. The scheduled snapshot and the associated restore feature can have data backed up by remote storage for extra security. By quickly reverting to previous storage states, users can be assured that their data is protected, even on top of the high level of existing redundancy.
Brand New Tools for VDI Applications
AccelStor’s special Free Clone function allows users to cut down on time-consuming volume cloning for VDI applications without allocating a physical capacity. AccelStor’s new vSphere Web Client Plug-in provides easy management for VMware administrators who can create, delete, and clone datastores in the integrated GUI, without needing to access the main web UI. Users can choose to enable thin provisioning or thick provisioning for greater flexibility when creating virtual disks. P710 is also certified for VAAI Block as VMware Ready Storage
Rock-Solid Reliability and Redundancy
All 24 SSDs in the NeoSapphire P710 are hot-swappable; 2 of these SSDs are hot spares for redundancy. In tandem with the new snapshot backup feature, this level of fault tolerance ensures that data is protected and always recoverable.
The 10GbE SKU of the NeoSapphire P710 is presently ready with available samples for customer evaluation. The Fibre Channel SKU will be available in January 2017. For product details and specifications, visit the NeoSapphire P710 product page: https://www.accelstor.com/overview.php?id=19
AccelStor is accelerating the paradigm shift from conventional disk arrays to modern all-flash storage. AccelStor's NeoSapphire series all-flash arrays, powered by FlexiRemap software technology, deliver sustained high IOPS to business-critical applications. With standard rack-mount form factors, streamlined storage management, multi-protocol support, as well as front-accessible and hot-swappable drives, NeoSapphire promises to resolve the performance bottlenecks for I/O-intensive applications like virtualization, high-performance computing, database, and media-processing applications. For more information about AccelStor and NeoSapphire, please visit www.accelstor.com.
* AccelStor, FlexiRemap, and NeoSapphire are trademarks or registered trademarks of AccelStor, Inc. in the United States of America and/or other countries.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers17.2.2018 21:00 | Pressemelding
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 08:00 | Pressemelding
Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 18:26 | Pressemelding
Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 17:05 | Pressemelding
General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges
Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 09:03 | Pressemelding
Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o
Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 08:00 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and